Drugs / BNT113
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03418480 | Apr 2017 → Nov 2023 | cancer of unknown primary site, head and neck neoplasm, human papillomavirus-related squamous cell carcinoma, penile cancer +1 | University of Southampton | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04534205 | Jan 2021 → Apr 2029 expected | head and neck squamous cell carcinoma | BioNTech SE | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-01-21 | BioNTech SE | BioNTech Receives FDA Fast Track Designation for mRNA Cancer Immunotherapy Candidate BNT113 in HPV16+ Head and Neck Cancer biontech.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT113 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03418480 ↗ |
| Modality | Vaccine | “Therapeutic HPV Vaccine (BNT113) Trial in HPV16 Driven Carcinoma” NCT03418480 ↗ |
| Route | Intravenous | “IV injection” NCT04534205 ↗ |